SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (830)1/10/2007 12:19:00 PM
From: zeta1961  Read Replies (1) | Respond to of 887
 
I listened to the JPMorgan webcast to feed masachoistic needs..

Wick anticipates filing IND compound '58747'..solid tumor agent..it's an oral and IV formulation

2 others on tap but no IND guidance:

-a dual aurora kinase inhibitor

-Akt targetting agent for breast

A-5 still accruing..They remain committed to Telcyta and hope that it'll find it's niche in earlier stage ovarian/lung cancers

-Assist data from all 3 trials will be presented at upcoming scientific conferences

P2 Telcyta triplicate in 1st line NSCLC will be presented at AACR..120 patient study

Telintra..start cytopenia P2..



To: tuck who wrote (830)1/10/2007 12:39:09 PM
From: keokalani'nui  Respond to of 887
 
Quarterly, yes. We see the report about 60 days later.

But they owned a gazzilllion shares of telk over a couple reporting periods. If they are using a reportable (e.g., option) derivative, they aren't going to take it off right before the filing deadline. Not just to hide that they are hedged. No way. But I don't really know.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News